Literature DB >> 20564467

Blood replacement with nanobiotechnologically engineered hemoglobin and hemoglobin nanocapsules.

Thomas Ming Swi Chang1.   

Abstract

Unlike donor red blood cells (RBCs), blood substitutes can be treated to remove infective agents and can be used on the spot or in the ambulance in emergency without the time-consuming typing and cross-matching. Donor RBC requires storage at 4 degrees and is only good for 42 days, but blood substitutes can be stored for much longer time. For example, a bovine polyhemoglobin (PolyHb) can be stored at room temperature for more than 1 year. It has been shown as far back as 1957 that artificial RBC can be prepared with ultrathin polymer membranes of nanodimension thickness. To increase the circulation time, the first-generation engineered hemoglobin (Hb) is formed by using glutaraldehyde to crosslink Hb into soluble nanodimension PolyHb that has been tested clinically in patients. Further extension includes conjugated Hb, intramolecularly crosslinked Hb and recombinant Hb. For certain clinical uses, in addition to engineered Hb, we also need antioxidants to remove oxygen radicals to prevent injury from ischemia reperfusion. Thus, we use nanobiotechnology to prepare second-generation engineered Hb by assembling Hb together with superoxide dismutase (SOD) and catalase (CAT) to form a nanodimension soluble complex of polyhemoglobin (PolyHb)-CAT-SOD. A third generation system is to prepare nanodimension complete artificial RBCs that can circulate for sufficient length of time after infusion. One approach uses lipid vesicles to encapsulate hemoglobin (Hb). Another approach is to use biodegradable polymer-like polylactic acid or a copolymer of polyethylene glycol-polylactide (PEG-PLA) to form the membrane of nanodimension complete artificial RBC (www.artcell.mcgill.ca). Copyright (c) 2010 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20564467      PMCID: PMC3518484          DOI: 10.1002/wnan.95

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol        ISSN: 1939-0041


  33 in total

1.  Extraction of erythrocyte enzymes for the preparation of polyhemoglobin-catalase-superoxide dismutase.

Authors:  Jingsong Gu; Thomas Ming Swi Chang
Journal:  Artif Cells Blood Substit Immobil Biotechnol       Date:  2009-02-18

2.  Stabilisation of enzymes by microencapsulation with a concentrated protein solution or by microencapsulation followed by cross-linking with glutaraldehyde.

Authors:  T M Chang
Journal:  Biochem Biophys Res Commun       Date:  1971-09-17       Impact factor: 3.575

3.  Cross-linked polyhemoglobin-superoxide dismutase-catalase supplies oxygen without causing blood-brain barrier disruption or brain edema in a rat model of transient global brain ischemia-reperfusion.

Authors:  D Douglas Powanda; Thomas M S Chang
Journal:  Artif Cells Blood Substit Immobil Biotechnol       Date:  2002-01

4.  Long-term effects on the histology and function of livers and spleens in rats after 33% toploading of PEG-PLA-nano artificial red blood cells.

Authors:  Zun Chang Liu; Thomas M S Chang
Journal:  Artif Cells Blood Substit Immobil Biotechnol       Date:  2008-12-09

5.  In vitro and in vivo effects of polyhaemoglobin-tyrosinase on murine B16F10 melanoma.

Authors:  Binglan Yu; Thomas Ming Swi Chang
Journal:  Melanoma Res       Date:  2004-06       Impact factor: 3.599

6.  Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes.

Authors:  Sunil V Rao; James G Jollis; Robert A Harrington; Christopher B Granger; L Kristin Newby; Paul W Armstrong; David J Moliterno; Lauren Lindblad; Karen Pieper; Eric J Topol; Jonathan S Stamler; Robert M Califf
Journal:  JAMA       Date:  2004-10-06       Impact factor: 56.272

7.  Polynitroxyl hemoglobin: a pharmacokinetic study of covalently bound nitroxides to hemoglobin platforms.

Authors:  Paul W Buehler; Chad R Haney; Anil Gulati; Li Ma; Carleton J C Hsia
Journal:  Free Radic Biol Med       Date:  2004-07-01       Impact factor: 7.376

8.  Effects of PEG-PLA-nano artificial cells containing hemoglobin on kidney function and renal histology in rats.

Authors:  Zun Chang Liu; Thomas M S Chang
Journal:  Artif Cells Blood Substit Immobil Biotechnol       Date:  2008

9.  Synthetic erythrocytes from lipid encapsulated hemoglobin.

Authors:  L Djordjevich; I F Miller
Journal:  Exp Hematol       Date:  1980-05       Impact factor: 3.084

10.  Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines, and other biologicals.

Authors:  T M Chang
Journal:  J Bioeng       Date:  1976-11
View more
  9 in total

1.  Polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase: a novel biotechnology-based blood substitute that transports both oxygen and carbon dioxide and also acts as an antioxidant.

Authors:  Yuzhu Bian; Zhixia Rong; Thomas Ming Swi Chang
Journal:  Artif Cells Blood Substit Immobil Biotechnol       Date:  2011-06

2.  Poly(ethylene glycol) cross-linked hemoglobin with antioxidant enzymes protects pancreatic islets from hypoxic and free radical stress and extends islet functionality.

Authors:  Venkatareddy Nadithe; Deepa Mishra; You Han Bae
Journal:  Biotechnol Bioeng       Date:  2012-04-08       Impact factor: 4.530

3.  2017 Military Supplement: Hemoglobin-based Oxygen Carriers: Current State-of-the-Art and Novel Molecules.

Authors:  Anirban Sen Gupta
Journal:  Shock       Date:  2017-09-29       Impact factor: 3.454

Review 4.  Bio-inspired nanomedicine strategies for artificial blood components.

Authors:  Anirban Sen Gupta
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-03-15

5.  Extraction of Phospholipids from Human Erythrocyte Membranes by Hemoglobin Oxidation Products.

Authors:  Linda S Brunauer; James Y Chen; M Zachary Koontz; Kathryn K Davis; Laura E O'Brien; Emily M Wright; Wray H Huestis
Journal:  J Membr Biol       Date:  2016-01-13       Impact factor: 1.843

6.  Nanobiotechnology and blood substitutes.

Authors:  Rajiv Saini; Santosh Saini; Sugandha Sharma
Journal:  Asian J Transfus Sci       Date:  2011-01

7.  Blood substitutes: Basic science, translational studies and clinical trials.

Authors:  Jonathan S Jahr
Journal:  Front Med Technol       Date:  2022-08-18

8.  Nanobiotechnological Nanocapsules Containing Polyhemoglobin-Tyrosinase: Effects on Murine B16F10 Melanoma Cell Proliferation and Attachment.

Authors:  Yun Wang; Thomas M S Chang
Journal:  J Skin Cancer       Date:  2012-11-08

Review 9.  Investigation on artificial blood or substitute blood replace the natural blood.

Authors:  Sh Keyhanian; M Ebrahimifard; M Zandi
Journal:  Iran J Ped Hematol Oncol       Date:  2014-04-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.